Epizyme Inc (EPZM)

14.20
0.55 4.00
NASDAQ : Health Care
Prev Close 13.65
Open 13.50
Day Low/High 13.25 / 14.35
52 Wk Low/High 8.27 / 23.35
Volume 707.51K
Avg Volume 742.20K
Exchange NASDAQ
Shares Outstanding 58.36M
Market Cap 846.19M
EPS -1.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

First Week of EPZM February 2018 Options Trading

Investors in Epizyme Inc. saw new options begin trading this week, for the February 2018 expiration.

Biotech Movers: AveXis, Clovis, Epizyme

Biotech Movers: AveXis, Clovis, Epizyme

AveXis, Clovis Oncology and Epizyme were among the biotech stock movers in premarket trading on June 20.

Epizyme's Positive Cancer Drug Results Likely to Catch the Eye of Celgene, J&J

Epizyme's Positive Cancer Drug Results Likely to Catch the Eye of Celgene, J&J

Epizyme sank almost 20% since their last earnings report, but recent developments show positive data from one of its keynote drugs, Tazemetostat

Alexion Pops, Biogen Falls on Executive Shuffle; Epizyme Recovers As Investors Digest Phase 2 Data

Alexion Pops, Biogen Falls on Executive Shuffle; Epizyme Recovers As Investors Digest Phase 2 Data

Epizyme, Alexion Pharmaceuticals and XBiotech were among the biotech stock movers premarket trading on June 14.

First Week of July 21st Options Trading For Epizyme (EPZM)

Investors in Epizyme Inc. saw new options become available this week, for the July 21st expiration.

Epizyme Announces Date Of First Quarter 2017 Financial Results And Tazemetostat Data Presentations At ASCO

Management to Host Conference Call on May 18, 2017 at 8:30 a.m. ET

Epizyme President Of Research And Chief Scientific Officer, Robert Copeland, Announces Retirement From The Company

Dr. Copeland to Remain a Key Advisor to Epizyme Following Transition

First Week of EPZM April 21st Options Trading

Investors in Epizyme Inc. saw new options begin trading this week, for the April 21st expiration.

Epizyme is Now Oversold (EPZM)

Epizyme is Now Oversold (EPZM)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Interesting EPZM Put And Call Options For August 18th

Interesting EPZM Put And Call Options For August 18th

Investors in Epizyme Inc. saw new options begin trading this week, for the August 18th expiration.

Commit To Purchase Epizyme At $10, Earn 27.3% Annualized Using Options

Commit To Purchase Epizyme At $10, Earn 27.3% Annualized Using Options

Investors considering a purchase of Epizyme Inc. shares, but cautious about paying the going market price of $11.80/share, might benefit from considering selling puts among the alternative strategies at their disposal.

Epizyme President Of Research And Chief Scientific Officer Named AAAS Fellow

Epizyme President Of Research And Chief Scientific Officer Named AAAS Fellow

Robert A. Copeland, Ph.D., recognized for his insights into epigenetic targets contributing to the development of novel investigational medicines

Epizyme Expands Clinical Programs Through Cooperative Research And Development Agreements With The National Cancer Institute

Epizyme Expands Clinical Programs Through Cooperative Research And Development Agreements With The National Cancer Institute

Studies Will Evaluate Tazemetostat and Pinometostat in Multiple Cancer Indications